. 2020 Apr 10;160(2):585–592.e2. doi: 10.1016/j.jtcvs.2020.04.005

Table E1.

Clinical characteristics and treatment of 11 postoperative patients infected with COVID-19

Case ID.	1	2	3	4	5	6	7	8	9	10	11
Severity of COVID-19	Critical	Critical	Critical	Severe	Severe	Severe	Severe	Mild	Mild	Mild	Mild
Date of surgery	2020/1/17	2020/1/2	2020/1/22	2020/1/16	2020/1/20	2020/1/16	2020/1/19	2020/1/16	2020/1/9	2020/1/20	2020/1/13
Positive exposure	NA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Date of post-op exposure	NA	2020/1/23	2020/1/23	2020/1/17	2020/1/20	2020/1/17	2020/1/19	2020/1/17	2020/1/20	2020/1/20	2020/1/25
date of COVID-19 test+	2020/1/21	2020/2/11	2020/2/12	2020/2/10	2020/2/3	2020/2/1	2020/2/3	2020/2/2	2020/2/8	2020/2/3	2020/2/22
Outcome	Death	Death	Death	Recovery	Recovery	Recovery	Recovery	Recovery	Recovery	Recovery	Recovery
Date of death/discharge	2020/1/22	2020/2/13	2020/2/26	2020/3/27	2020/3/6	2020/2/23	2020/3/21	2020/3/5	2020/2/29	2020/2/29	2020/3/25
Onset symptoms	Fever	Fever	Fever	Dyspnea	Fever	Fever	Dyspnea	Fever	Dry cough	Fever	Fever
Fever peak (°C)	39.5	38.7	39.6	39.0	39.4	39.3	38.4	38.6	38.0	38.4	38.4
Normothermia for 3 d	No	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dyspnea	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Chest tightness	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Fatigue	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes
Dry cough	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes
Loss of appetite	No	Yes	Yes	Yes	No	No	Yes	No	Yes	No	Yes
Nausea	Yes	Yes	Yes	No	No	Yes	No	No	Yes	No	Yes
Headache	Yes	Yes	Yes	No	No	No	Yes	No	Yes	No	Yes
Sputum	Yes	Yes	No	No	Yes	No	Yes	No	No	No	No
Diarrhea	Yes	No	Yes	Yes	No	No	No	No	No	No	No
Dizziness	Yes	No	No	No	No	No	No	No	Yes	No	No
Rhinorrhea	No	Yes	No	No	No	No	No	No	No	No	No
Pleural effusion	No	Yes	Yes	No	Yes	No	No	No	Yes	Yes	Yes
SaO₂ <93%	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Nadir SaO₂ (%)	85	80	60	92	90	92	92	97	98	94	95
Leukocytosis	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Leukopenia	Yes	No	No	No	No	No	No	No	Yes	Yes	No
Lymphopenia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Eosinopenia	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lowest eosinophils, ×10⁹/L	0	0	0	0	0	0	0	0.01	0	0	0
Elevation of AST or ALT	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
AST increase	No	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes
ALT increase	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Peak LDH value, U/L	348	664	618	233	354	309	613	263	349	253	347
Reduction in total protein, g/L	16.1	21.0	9.7	5.2	6.2	8.2	15.4	6.0	13.7	8.3	2.0
Reduction in albumin, g/L	12.0	14.0	17.9	3.5	2.2	3.5	9.9	4.7	8.0	10.2	2.4
Nadir of lymphocytes, ×10⁹/L	0.18	0.29	0.28	0.28	0.39	0.25	0.68	1.20	0.23	0.65	0.28
Oxygen supplementation	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Mechanical ventilation	BPAP	IMV	IMV	No	No	No	No	No	No	No	No
Corticosteroid	No	No	Yes	Yes	Yes	Yes	Yes	No	No	No	No
Anti-viral therapy	O	O + U	O + U	O + U	O + U	O + L + R	O	O + U	O + U	O	O + U
IV IgG	No	No	Yes	No	No	No	Yes	No	No	Yes	No

COVID-19, Coronavirus disease 2019; NA, not available; Post-op, postoperative; SaO₂, oxygen saturation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BPAP, bilevel positive airway pressure; IMV, intermittent mandatory ventilation; O, oseltamivir; U, umifenovir; L, lopinavir; R, ritonavir; O + U, O + L, O + R, oseltamivir has been replaced by umifenovir, lopinavir, or ritonavir, no one received combined antiviral therapy; IV IgG, intravenous immunoglobulin G.